EW (Edwards Lifesciences Corporation) Stock Financials & Earnings

EWEdwards Lifesciences Corporation

Mkt Cap$50B

Healthcare·Medical - Devices·🇺🇸 United States·NYSE

Revenue (TTM)$6.1B

Net Income (TTM)$1.1B

EPS (TTM)$1.83

Free Cash Flow (TTM)$1.3B

Gross Margin78.1%

Op. Margin26.7%

Net Margin17.6%

FCF Margin22.0%

P/S Ratio (TTM)8.2x

P/E Ratio (TTM)46.3x

YoY Rev Growth+11.2%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$1.5B	$1.1B	$403M
Q2 23	$1.3B	$1.0B	$371M
Q3 23	$1.2B	$971M	$347M
Q4 23	$1.3B	$1.0B	$357M
Q1 24	$1.3B	$1.0B	$356M
Q2 24	$1.4B	$1.1B	$365M
Q3 24	$1.4B	$1.1B	$351M
Q4 24	$1.4B	$1.1B	$313M
Q1 25	$1.4B	$1.1B	$395M
Q2 25	$1.5B	$1.2B	$431M
Q3 25	$1.6B	$1.2B	$425M
Q4 25	$1.6B	$1.2B	$370M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Quarter	Critical Care	Surgical Heart Valve Therapy	Transcatheter Heart Valves	Transcatheter Mitral And Tricuspid Therapies
Q1 23	$222M	$248M	$948M	$42M
Q2 24	—	$264M	$1.0B	$83M
Q3 24	—	$240M	$1.0B	$91M
Q4 24	—	$211M	$1.0B	$105M
Q1 25	—	$251M	$1.0B	$115M
Q2 25	—	$267M	$1.1B	$135M
Q3 25	—	$258M	$1.1B	$145M
Q4 25	—	$254M	$1.2B	$156M

Revenue by Geography

Quarter	Europe	Japan	Rest of World	United States
Q1 23	$331M	$114M	$165M	$849M
Q2 24	$336M	$87M	$146M	$817M
Q3 24	$320M	$81M	$149M	$805M
Q1 25	$342M	$82M	$150M	$839M
Q2 25	$378M	$95M	$169M	$890M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$873M	$382M	$1.3B
Q2 23	$1.0B	$467M	$1.5B
Q3 23	$1.4B	$454M	$1.9B
Q4 23	$1.1B	$501M	$1.6B
Q1 24	$1.2B	$473M	$1.7B
Q2 24	$1.6B	$345M	$2.0B
Q3 24	$3.7B	$770M	$4.4B
Q4 24	$3.0B	$931M	$4.0B
Q1 25	$3.1B	$758M	$3.9B
Q2 25	$3.3B	$789M	$4.1B
Q3 25	$2.7B	$1.2B	$3.8B
Q4 25	$2.9B	$1.3B	$4.2B

Shares Outstanding

Revenue Per Employee

Revenue / Employee